Recital 11, Regulation (EU) 2024/2699

In forcesince 18 Oct 2024

In order to allow for a more informative decision making and for exchange of information and pooling of knowledge, the Coordination Group, with the facilitation of the HTA secretariat, should ensure appropriate exchange of information with the European Medicines Agency on horizontal issues of scientific or technical nature related to joint clinical assessment and joint scientific consultation, such as methodological issues following international standards of evidence-based medicine. In order to preserve the separation of the respective remits of the Coordination Group and the European Medicines Agency, these exchanges should not relate to the assessment of individual health technologies. The Coordination Group should also be able to involve in this exchange of information the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282 (‘the HTA stakeholder network’).